Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02988843
Recruitment Status : Suspended (Funding Unavailable)
First Posted : December 9, 2016
Last Update Posted : September 26, 2018
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : February 2021
  Estimated Study Completion Date : February 2021